The 15th JFCR−ISCC

December 2-3, 2010
Hotel Nikko Tokyo, Tokyo

The 15th JFCR-International Symposium on Cancer Chemotherapy (ISCC) is scheduled on December 2 (Thu) and 3 (Fri), 2010, at the Hotel Nikko Tokyo, Daiba, Tokyo, Japan. I sincerely like to ask you to participate in the Symposium.
The Symposium (JFCR-ISCC) aims at exchanging and discussing the latest information on cancer chemotherapy focusing on clinical development of new anti-cancer drugs and future perspectives at the global level. Application trials of genomic technologies and bioinformatics become a major trend in clinical development of new anti-cancer drugs today. However, their impacts on this field are still dependent on cases and need to be experienced with more drugs and occasions. Updating information on favored and also un-favored cases in world-wide clinical trials would be essential for improvement of our own status. In coming 15th Symposium, new developing strategies of tyrosine kinase inhibitors, TGFβ signal inhibitors in relation to cancer stem cells, drug-conjugated antibody and developing better combination therapy are scheduled to be discussed as major topics. I believe this occasion would be an excellent opportunity for you to access the domestic and international information on clinical trials of cancer chemotherapy.
Many international co-operative studies are in fact ongoing for developing new anti-cancer drugs and such world-wide, harmonized study should become much more important in the future. I hope the Symposium will both encourage international cooperation in cancer chemotherapy and stimulate basic and clinical investigators in Japan.
Looking forward to seeing you in the Symposium,

Mitsuaki Yoshida, PhD
Chairman, JFCR-ISCC
Director, Cancer Chemotherapy Center
Japanese Foundation for Cancer Research (JFCR)

(*Program update)

December 2, 2010 (Thursday)

12:00-12:30

(Committee Meeting)

Opening Remark

13:00-13:10

Mitsuaki Yoshida (Cancer Chemotherapy Center, Tokyo)

I Nuclear Targets

Chairpersons: Jean-Pierre Armand (Institut Claudius Regaud, Toulouse)
Saburo Sone (Tokushima University, Tokushima)

13:10-13:45

Jaap Verweij (Erasmus University Medical Center, Rotterdam)

Clinical progress with PARP inhibition

13:45-14:20

Yves G. Pommier (National Cancer Institute, Bethesda)

Novel topoisomerases inhibitors in early clinical trials

14:20-14:30

Discussion

14:30-14:50

Coffee Break

II PI3 kinase inhibitors

Chairpersons: Barbara Klencke (Genentech, South San Francisco)
Michihiko Kuwano (Kyushu University, Fukuoka)

14:50-15:25

Takao Yamori (Cancer Chemotherapy Center, Tokyo)

Characterization of a new PI3 kinase inhibitor ZSTK474

15:25-16:00

Josep Tabernero (Vall d'Hebron University Hospital, Barcelona)

PI3K inhibitors, BEZ235 and BKM120

16:00-16:10

Discussion

III New drugs and new targets

Chairpersons: Tomoki Naoe (Nagoya University, Nagoya)
Yoshimasa Uehara (Iwate Medical University, Morioka)

16:10-16:45

Masuo Yamaoka (Takeda Pharmaceutical Co. Ltd., Tsukuba)

Antiandrogens for prostate cancer therapy

16:45-17:20

Karl-Heinz Altmann (Eidgenössische Technische Hochschule Zürich, Zürich)

Epothilones as lead structures for anticancer drug discovery

17:20-17:50

*Barbara Klencke (Genentech, South San Francisco)

Trastuzumab-DM1(T-DM1) antibody-drug conjugate (ADC): Bridging targeted therapy and conventional chemotherapy

17:50-18:00

Discussion

18:10-19:40

Mixer

December 3, 2010 (Friday)

IV Tyrosine kinase inhibitors

Chairpersons: Jaap Verweij (Erasmus University Medical Center, Rotterdam)
Yoshikazu Sugimoto (Keio University, Tokyo)

09:00-09:35

Shinya Kimura (Saga University, Saga)

Abl tyrosine kinase inhibitors

09:35-10:10

Hiroyuki Mano (Jichi Medical University, Tochigi/University of Tokyo, Tokyo)

Targeting ALK-fusion kinases

10:10-10:45

Mark Ratain (University of Chicago, Chicago)

Brivanib, a combined VEGFR and FGFR inhibitor

10:45-10:55

Discussion

10:55-11:15

Coffee Break

Special Lecture I

Chairperson: Tetsuichiro Muto (Cancer Institute Hospital, Tokyo)

11:15-11:55

Bruce A. Chabner (MGH Cancer Center, Boston)

Finding optimal combinations of molecular targeted agents

Luncheon Seminar I

Sponsored by University of Tokyo, Pharmaceutical Sciences Alumni

Chairperson: Toshihiko Kobayashi (University of Tokyo)

12:10-13:10

Karl-Heinz Altmann (Eidgenössische Technische Hochschule Zürich)

Kinase inhibitors as anticancer drugs: potential and limitation

Luncheon Seminar II

Sponsored by Novartis Pharma KK and EFPIA

Chairperson: Ken Kobayashi (Novartis Pharma KK)

12:10-13:10

Josep Tabernero (Vall d'Hebron University Hospital, Barcelona)

An overview of the different approaches to inhibit the PI3K pathway

Special Lecture II

Chairperson: Yves G. Pommier (National Cancer Institute, Bethesda)

13:30-14:10

Kohei Miyazono (University of Tokyo, Tokyo)

TGF-β signaling for the maintenance of glioma-initiating cells

V Cancer stem cells and TGF-beta signaling

Chairpersons: Mark Ratain (University of Chicago, Chicago)
Yoshiro Niitsu (Sapporo Medical University, Sapporo)

14:10-14:45

Atsushi Hirao (Kanazawa University, Kanazawa)

Molecular mechanisms regulating maintenance of leukemia stem cells

14:45-15:15

Karl-Hermann Schlingensiepen (Antisense Pharma, Regensburg)

Targeted tumor treatment with Trabedersen (AP12009)

15:15-15:25

Discussion

15:25-15:45

Coffee Break

VI New modes for drug development

Chairpersons: Bruce A. Chabner (MGH Cancer Center, Boston)
Takao Yamori (Cancer Chemotherapy Center, Tokyo)

15:45-16:15

*Jennifer Low (Genentech, South San Francisco)

Hedgehog pathway inhibitor GDC-0449 in oncology

16:15-16:50

Jean-Pierre Armand (Institut Claudius Regaud, Toulouse)

Phase 0 clinical trial oncology/Microdosing

16:50-17:00

Discussion

Closing Remark

17:00-17:10

Bruce A Chabner (MGH Cancer Center, Boston)

For further information

please contact:
Masako Sasaki
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Ariake 3-8-31, Koto-ku, Tokyo 135-8550, Japan
TEL: 81-3-3520-0111 (ex. 5413) FAX: 81-3-3570-0482

Page TOP